Ajaypal Singh to Cardiovascular Diseases
This is a "connection" page, showing publications Ajaypal Singh has written about Cardiovascular Diseases.
Connection Strength
1.242
-
Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: pro. J Am Soc Nephrol. 2009 Jul; 20(7):1436-41.
Score: 0.249
-
Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease. Reply. N Engl J Med. 2022 12 29; 387(26):2482-2485.
Score: 0.159
-
Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021 12 16; 385(25):2325-2335.
Score: 0.147
-
Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. N Engl J Med. 2021 12 16; 385(25):2313-2324.
Score: 0.147
-
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2019 03; 73(3):309-315.
Score: 0.120
-
C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2016 Dec; 68(6):873-881.
Score: 0.103
-
Anemia in chronic kidney disease: new advances. Heart Fail Clin. 2010 Jul; 6(3):347-57.
Score: 0.067
-
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2009 Jul; 54(1):59-69.
Score: 0.062
-
The target hemoglobin in patients with chronic kidney disease. Nephrol News Issues. 2006 Dec; 20(13):29-30.
Score: 0.052
-
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J. 2005 Mar; 149(3):408-13.
Score: 0.046
-
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2019 05; 21(5):1199-1208.
Score: 0.030
-
BP in Dialysis: Results of a Pilot Study. J Am Soc Nephrol. 2018 01; 29(1):307-316.
Score: 0.028
-
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010 Sep 16; 363(12):1146-55.
Score: 0.017
-
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009 Nov 19; 361(21):2019-32.
Score: 0.016